- Accueil >
- Publications >
- Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations
Auteurs
Céline Greco, Stéphanie Leclerc-Mercier, Sarah Chaumon, François Doz, Smail Hadj-Rabia, Thierry Molina, Claude Boucheix, Christine Bodemer